NEW YORK (GenomeWeb) – Plant genome engineering firm Calyxt announced today that it has priced its planned initial public offering of 7 million shares at $8 per share, for gross proceeds of $56 million.

Calyxt had previously said that it intended to float 6.06 million shares at between $15 and $18 apiece, which would have raised $90.9 million to $109.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.